Novartis positions itself as eye care giant with Alcon merger
Novartis on Wednesday announced that its merger agreement with Alcon has been settled to the tune of $12.9 billion. The new $8.7 billion Alcon eye care division, which includes CIBA Vision and selected ophthalmic medicines, will be led by current Alcon president and CEO Kevin Buehler.
Post a Comment
Footer Content
Retail Group
Events - Retail
Industry Guides, Research & Reports
International
footer
© 2012 Drug Store News. All Rights Reserved.